Table 1 Characteristics of study population according to type of endocrine therapy initiated at study enrollment.
Characteristic | Overall Study Population N = 321 | Tamoxifen N = 140 | Aromatase Inhibitor N = 181 |
|---|---|---|---|
Median (Q1-Q3) age in years | 63 (56–71) | 54 (49–59) | 69 (64–74) |
Post-menopausal – N (%) | 210 (65.4) | 34 (24.3) | 176 (97.2) |
Ovarian Function Suppression – N (%) | 17 (5.3) | 16 (11.4) | 1 (0.6) |
Switching Endocrine Therapya – N (%) | 6 (1.9) | 0 (0) | 6 (3.3) |
Race – N (%) | |||
White | 268 (83.5) | 112 (80) | 156 (86.2) |
Black | 33 (10.3) | 16 (11.4) | 17 (9.4) |
Other | 20 (6.2) | 12 (8.6) | 8 (4.4) |
Neighborhood Poverty Rateb – N (%) | |||
0–15% | 274 (85.9) | 116 (82.9) | 158 (88.3) |
>15% | 45 (14.1) | 24 (17.1) | 21 (11.7) |
Median number of concomitant medications at enrollment (range) | 4 (0–29) | 3 (0–29) | 5 (0–22) |
Stage – N (%) | |||
0 | 28 (8.7) | 18 (12.9) | 10 (5.5) |
I | 191 (59.5) | 80 (57.1) | 111 (61.3) |
II | 79 (24.6) | 39 (27.9) | 40 (22.1) |
III | 23 (7.2) | 3 (2.1) | 20 (11) |
ER-positive – N (%)c | 320 (100) | 139 (100) | 181 (100) |
PR-positive – N (%)c | 282 (88.7) | 128 (93.4) | 154 (85.1) |
HER2-positive – N (%) | 26 (8.9) | 10 (8.2) | 16 (9.4) |
Mastectomy – N (%) | 143 (44.5) | 76 (54.3) | 67 (37) |
Radiation – N (%) | 215 (67) | 85 (60.7) | 130 (71.8) |
Chemotherapy – N (%) | 90 (28.2) | 43 (30.9) | 47 (26.1) |
Median duration of follow-up in months (range)d | 56.1 (6.9–87.7) | 57.9 (9.1–87.7) | 54.4 (6.9–87.3) |
